Health Trials

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

1

Review clinical trials related to KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.

Participants needed: 588
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu HengRui Medicine Co., Ltd.Updated: Jul 15, 2026Locations: 1
Eligibility criteria

Able and willing to provide a written informed consent [+5]

Any other condition that, in the judgment of the investigator, may increase the... [+11]

Read more